Corticosteroid Therapy in Glomerulonephritis
نویسندگان
چکیده
منابع مشابه
Corticosteroid and immunosuppressive treatment in glomerulonephritis. (Literature review).
During the past decades corticosteroids and immunosuppressirve agents are widel~ used liln the treatment of g1lomeru!l.roneph!iiltis, based on the assumption that many forms of glomerular diseases have an immunologic basi!s '(Dixon, 1968). Acute and chronic toxicity produced by these drugs jUJstifies the physician to know exac·Uy about the naturaJ history of 1:Jhe disease. Sim.ce the use of clo...
متن کاملCorticosteroid therapy in IgA nephropathy.
The benefits and risks of steroids for the treatment of IgA nephropathy remain uncertain. We systematically searched MEDLINE, EMBASE, and the Cochrane Library for randomized, controlled trials of corticosteroid therapy for IgA nephropathy published between 1966 and March 2011. We identified nine relevant trials that included 536 patients who had urinary protein excretion >1 g/d and normal renal...
متن کاملCorticosteroid therapy in Riedel's thyroiditis.
We report a case of Riedel's thyroiditis presenting with a systemic illness, life-threatening stridor and a stony hard goitre. Diagnosis was confirmed by open thyroid biopsy. Treatment with corticosteroid resulted in a dramatic improvement. A possible autoimmune mechanism in the pathogenesis of Riedel's thyroiditis is discussed.
متن کاملIatrogenic Cushing\'s Syndrome Due to Cutaneous Corticosteroid Therapy
Summary A case of Cushing' s syndrome associated with application of topical clobetasol propionate (0.05%) is reported. Local application of clobetasol propionate is associated with adrenal suppression in normal subjects and on this basis, it has been recommended that less than 50 g per week be used. There have been sporadic case reports of cushing's syndrome associated with topical steroid bu...
متن کاملRole of rituximab therapy in glomerulonephritis.
B cell depletion with the monoclonal antibody rituximab is attracting increasing attention in systemic lupus erythematosus, vasculitis, and primary glomerulonephritis. Existing, uncontrolled data report high response rates in patients with refractory disease. If supported by the results of ongoing randomized trials, then rituximab and related B cell-depleting or -modulating drugs are likely to ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Internal Medicine
سال: 1998
ISSN: 0918-2918,1349-7235
DOI: 10.2169/internalmedicine.37.651